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Background: A recent genome-wide association study (GWAS) using chronic HBV (hepatitis B virus) carriers with
and without hepatocellular carcinoma (HCC) in five independent Chinese populations found that one SNP
(rs17401966) in KIF1B was associated with susceptibility to HCC. In the present study, a total of 580 HBV-derived
HCC cases and 1351 individuals with chronic hepatitis B (CHB) or asymptomatic carrier (ASC) were used for
replication studies in order to evaluate the reported association with HBV-derived HCC in other East Asian
populations.
Results: We did not detect any associations between rs17401966 and HCC in the Japanese cohorts (replication 1:
OR = 1.09, 95 % CI = 0.82-1.43; replication 2: OR = 0.79, 95 % CI = 0.54-1.15), in the Korean cohort (replication 3:
OR = 0.95, 95 % CI = 0.66-1.36), or in the Hong Kong Chinese cohort (replication 4: OR = 1.17, 95 % CI = 0.79-1.75).
Meta-analysis using these cohorts also did not show any associations with P = 0.97.
Conclusions: None of the replication cohorts showed associations between rs17401966 and HBV-derived HCC. This
may be due to differences in the genetic diversity among the Japanese, Korean and Chinese populations. Other
reasons could be the high complexity of multivariate interactions between the genomic information and the
phenotype that is manifesting. A much wider range of investigations is needed in order to elucidate the differences
in HCC susceptibility among these Asian populations.
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Hepatitis B (HB) is a potentially life-threatening liver in-
fection caused by the hepatitis B virus (HBV), and ap-
proximately 360 million people worldwide are thought
to be chronically infected with HBV. The clinical course
of HBV infection is variable, including acute self-limiting
infection, fulminant hepatic failure, inactive carrier state
and chronic hepatitis with progression to cirrhosis and* Correspondence: sawai@m.u-tokyo.ac.jp
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reproduction in any medium, provided the orhepatocellular carcinoma (HCC). Although some HBV
carriers spontaneously eliminate the virus, 2-10 % of
individuals with chronic HB (CHB) develop liver cirrho-
sis every year, and a subset of these individuals suffer
from liver failure or HCC. Around 600,000 new HCC
cases are diagnosed annually worldwide, with HCC
being relatively common in Asia-Pacific countries and
sub-Saharan Africa; more than 70 % of HCC patients are
diagnosed in Asia (with 55 % in China) [1]. However,
HCC is relatively uncommon in the USA, Europe and
Australia [1,2]. The majority of HCC develops in
patients with cirrhosis, which is most often attributabletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Sawai et al. BMC Medical Genetics 2012, 13:47 Page 2 of 4
http://www.biomedcentral.com/1471-2350/13/1/47to chronic HBV infection followed by chronic HCV in
the Asia-Pacific region [3].
A recent genome-wide association study (GWAS)
using Japanese CHB cases and controls confirmed that
11 SNPs in a region including HLA-DPA1 and -DPB1
were associated with CHB [4]. Moreover, a GWAS using
chronic HBV carriers with and without HCC in five in-
dependent Chinese populations reported that one SNP
(rs17401966) in KIF1B was associated with HCC suscep-
tibility [5]. In the present study, we performed replication
studies using Japanese, Korean and Hong Kong Chinese
cases and controls in order to evaluate the reported
association with HBV-derived HCC in other East Asian
populations.
Results
We performed SNP genotyping of rs17401966 located in
the KIF1B gene for the purpose of replication analysis of
the previous GWAS report [5]. Four distinct cohorts
were used for these replication analyses (Table 1). We
first examined two independent Japanese case–control
samples including 179 cases and 769 controls from
Biobank Japan (replication 1), and 142 cases and 251 con-
trols from various hospitals (replication 2). We did not de-
tect any associations between rs17401966 and HCC in the
Japanese cohorts (replication 1: OR = 1.09; 95 % CI =
0.82-1.43, replication 2: OR=0.79; 95 % CI= 0.54-1.15).
We further examined Korean case–control samples com-
prising 164 cases and 144 controls (replication 3) and
Hongkongese 94 HCC cases and 187 CHB controls (repli-
cation 4), but again did not detect any association
(replication 3: OR = 0.95; 95 % CI = 0.66-1.36, replica-
tion 4: OR=1.17; 95 % CI=0.79-1.75). Logistic regression
analysis adjusted for age and gender also did not show any
association (Plog = 0.65, 0.27, 0.11, 0.56 for each replicationTable 1 Association between rs17401966 and HBV-derived H
cohort sample size cases cont
(cases/controls) GG AG AA GG
replication 1 179/769 13 61 105 45
(Japan 1) (7.2) (34.1) (58.7) (5.9)
replication 2 142/251 5 46 91 14
(Japan 2) (3.5) (32.4) (64.1) (5.6)
replication 3 164/144 17 59 88 15
(Korea) (10.4) (36.0) (53.6) (10.4
replication 4 94/187 10 39 44 13
(Hong Kong) (10.6) (41.5) (46.8) (6.9)
Meta-analysis c
aP value of fisher’s exact test for allele model.
bResult of Breslow-Day test.
cResults of meta-analysis were calculated by the Mantel-Haenzel method.panel). Moreover, we conducted meta-analysis to combine
these studies, also not detect any association (Pmeta = 0.97).
Discussion and conclusions
Zhang et al. [5] reported that SNP rs17401966 was
significantly associated with HBV-related HCC (joint
OR = 0.61). They conducted a GWAS using 348 cases
and 359 controls in a population in Guangxi in
southern China, and selected 45 SNPs for the replica-
tion study based on the results (P< 10-4). In the first
replication study, they used 276 cases and 266 controls
from Beijing in northern China, and 5 SNPs showed the
same direction of association as in the GWAS (P< 0.05).
They performed a further replication study (of 507 cases
and 215 controls) in Jiangsu in eastern China and
only one SNP showed the same trend (P=3.9×10-5).
Guangdong and Shanghai samples from southern and east-
ern China were used for further replication studies. The as-
sociation yielded a p-value of 1.7×10-18 on meta-analysis.
We performed four replication analyses using Japanese,
Korean and Hong Kong Chinese samples (Table 1). Al-
though sample size of each cohort is smaller than that of
the previous GWAS, we conducted mete-analysis of all
our study. The result did not show any association be-
tween rs17401966 and HBV-derived HCC (Pmeta = 0.97).
This may be due to differences in genetic diversity
among Japanese, Korean and Chinese populations. A
maximum-likelihood tree of 126 populations based on
19,934 SNPs showed that Japanese and Korean popu-
lations form a monophyletic clade with a 100 % boot-
strap value [6]. However, Chinese populations form a
paraphyletic clade with two other populations. This
indicates that Japanese and Korean populations are
genetically closer to one another than the Chinese
population.CC
rols OR
AG AA HWE p (95 % CI) P a Phet
b
261 463 0.599 1.09 0.578
(33.9) (60.2) (0.82-1.43)
91 146 1 0.79 0.212
(36.2) (58.2) (0.54-1.15)
55 74 0.616 0.95 0.790
) (38.2) (51.4) (0.66-1.36)
80 94 0.767 1.17 0.432
(42.8) (50.3) (0.79-1.75)
0.996 0.965 0.423
(0.84-1.18)
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Chinese cohort (P = 0.43). Moreover, a study using 357
HCC cases and 354 HBV-positive non-HCC controls in
Hong Kong Chinese did not show any significant differ-
ence (P= 0.91) [7]. Previous population studies have
revealed that various Han Chinese populations show vary-
ing degrees of admixture between a northern Altaic clus-
ter and a southern cluster of Sino-Tibetan/Tai-Kadai
populations in southern China and northern Thailand [6].
Although Hong Kong is located closed to the Guangdong
(cohort 3 of Zhang et al study), there is great heterogen-
eity for rs17401966 between Hong Kong cohorts (our
study and Chan’s study [7]) and Guangdong cohort (our
study versus Zhang’s study: Phet = 0.0066; Chan’s study ver-
sus Zhang’s study: Phet = 0.035). This result suggests the
existence of other confounding factors, which can differ-
entiate the previous study in China and this study.
One of the possible reasons could be the high com-
plexity of multivariate interactions between the genomic
information and the phenotype that is manifesting. HCC
development is a multiple process which links to causa-
tive factors such as age, gender, environmental toxins, al-
cohol and drug abuse, higher HBV DNA levels, and
HBV genotype variations [8]. The eight HBV genotypes
display distinct geographical and ethnic distributions.
Genotypes B and C are prevalent in Asia. Specific varia-
tions in HBV have been associated with cirrhosis and
HCC. These variations include in particular mutations in
pre-core region (Pre-C), in basal core promoter (BCP) and
in ORF encoding Pre-S1/Pre-S2/S and Pre-C/C. Because
there is an overlap between Pre-C or BCP mutations and
genotypes, these mutations appear to be more common in
genotype C as compared to other genotypes [9].
Aflatoxins are a group of 20 related metabolites and
Aflatoxin B1 is the most potent naturally occurring chem-
ical liver carcinogen known. Aflatoxin exposures multipli-
catively increase the risk of HCC in people chronically
infected with HBV, which illustrates the deleterious im-
pact that even low toxin levels in the diet can have on
human health [10–12]. Liu and Wu estimated population
risk for aflatoxin-induced HCC around the world [13].
Most cases occur in sub-Saharan Africa, Southeast Asia
and China, where populations suffer from both high HBV
prevalence and largely uncontrolled exposure to aflatoxin
in food. But we could not obtain the information of these
confounding factors from both of the previous GWAS
study and this study. A much wider range of investigations
is thus needed in order to elucidate the differences in
HCC susceptibility among these Asian populations.
Methods
Samples
Case and control samples used in this study were collected
from Japan, Korea and Hong Kong listed in supplementaryAdditional file 1: Table S1. A total of 179 cases and 769
control subjects were analyzed in the first replication study.
DNA samples from both CHB controls and HBV-related
HCC cases used in this study were obtained from the
BioBank Japan at the Institute of Medical Science, the
University of Tokyo [14]. Among the BioBank Japan sam-
ples, we selected HBsAg-seropositive CHB patients with
elevated serum aminotransferase levels for more than six
months, according to the guidelines for diagnosis and
treatment of chronic hepatisis from The Japan Society of
Hepatology (http://www.jsh.or.jp/medical/gudelines/index.
html). The mean (and standard deviation; SD) age was 62.0
(9.4) years for the cases and 54.7 (13.5) years for the con-
trols. The second Japanese replication sample sets for the
cases (n=142) and controls (n=251) study were obtained
from 16 hospitals. The case samples for the second repli-
cation included 142 HCC patients and the controls
included 135 CHB patients and 116 asymptomatic carriers
(ASC). The mean (SD) age was 61.3 (10.2) years for the
cases and 56.2 (10.9) years for the controls. The Korean
replication samples were collected from Yonsei University
College of Medicine. The third replication set was com-
posed of 165 HCC patients and 144 CHB patients. The
mean (SD) age was 52.2 (8.9) and 37.3 (11.3) years for the
cases and controls, respectively. The samples in Hong
Kong were collected from the University of Hong Kong,
Queen Mary Hospital. The fourth replication set was
composed of 94 HCC patients and 187 CHB patients. The
mean (SD) age was 58.0 (10.5) and 56.9 (8.3) years for the
cases and controls, respectively. All participants provided
written informed consent. This research project was
approved by the Research Ethics Committees at the
Institute of Medical Science and the Graduate School of
Medicine, the University of Tokyo, Yonsei University
College of Medicine, the University of Hong Kong, Nationa
Center for Global Health and Medicine, Hokkaido
University Graduate School of Medicine, Teine Keijinkai
Hospital, Iwate Medical University, Saitama Medical
University, Kitasato University School of Medicine,
Musashino Red Cross Hospital, Kanazawa University
Graduate School of Medicine, Shinshu University School of
Medicine, Nagoya City University Graduate School of
Medical Sciences, Kyoto Prefectural University of Medicine,
National Hospital Organization Osaka National Hospital,
Kawasaki Medical College, Tottori University, Ehime
University Graduate School of Medicine, and Kurume
University School of Medicine.
SNP Genotyping
For the first replication samples, we genotyped rs17401966
using PCR-based Invader assay (Third Wave Technologies,
Madison, WI) [15], and for the second, third and fourth
replication samples, we used TaqMan genotyping assay
(Applied Biosystems, Carlsbad, CA). In the TaqMan SNP
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5-μl reaction mixture containing 1 μl of genomic DNA,
2.5 μl of KAPA PROBE FAST qPCR Master Mix (Kapa
Biosystems, Woburn, MA), and 40 x TaqMan SNP
Genotyping Assay probe (ABI) for this SNP. QPCR thermal
cycling was performed as follows: 95°C for 3 min, followed
by 40 cycles of 95°C for 15 s and 60°C for 1 min. The SNP
call rate of each replication panel was 100 %, 100 %, 99.7 %
and 99.6 %.
Statistical analysis
We performed Hardy-Weinberg equilibrium test for the
case and control samples in each replication study. Fisher’s
exact test was applied to two-by-two contingency tables for
three different genetic models; allele frequency, dominant
and recessive model. Odds ratios and confidence intervals
were calculated using the major alleles as references. Meta-
analysis was conducted using the Mantel-Haenszel method.
Heterogeneity among studies was examined by using the
Breslow-Day test. Genotype-phenotype association for the
SNP rs17401966 was assessed using logistic regression ana-
lysis adjusted for age and gender in plink 1.07 (http://pngu.
mgh.harvard.edu/~purcell/plink/index.shtml).
Additional fileAdditional file 1: Table S1. Samples used in this study.
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